Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- CMIC Aims at Becoming Pharmaceutical Value Creator
November 20, 2006
- Eisai: Major Products Contribute to Strong Growth in 1st Half
November 13, 2006
- Roche Diagnostics' ACCU-CHEK Aviva Awarded Good Design Prize
November 13, 2006
- Kyowa Hakko: Consolidated Sales Down 2.4%
November 13, 2006
- Korosho to Build Nationwide Clin. Trial Network by Therapeutic Field
November 13, 2006
- Torii: NHI Price Revision, GE Competition Hit Sales, Profits
November 13, 2006
- Off-label Use Points Up Weakness of Domestic Clin. Research: Mr Sato
November 13, 2006
- Asahi Kasei Pharma: Profits Up Despite Decline in Sales
November 13, 2006
- R&D NEWS IN BRIEF
November 13, 2006
- CMIC Starts Contract Genetic Polymorphism Analysis Business
November 13, 2006
- Antiviral Peptide Found in Ashitaba: Takara Bio
November 13, 2006
- BUSINESS NEWS IN BRIEF
November 13, 2006
- Only 23.5% of Pharma Universities Treat Self-medication as Individual Subject: SMAC
November 13, 2006
- Survey Sees Increase in Women MRs, MR Reemployment
November 13, 2006
- Most Members Dissatisfied with Pharm. Associations: JACDS
November 13, 2006
- Nihon Chouzai: Double-Digit Drop in Profits Despite 12% Rise in Sales
November 13, 2006
- SELF-MEDICATION NEWS IN BRIEF
November 13, 2006
- Council Urges Quick Development and Approval of 3 Drugs
November 13, 2006
- Social Security Benefits Rose 1.6% in FY2004
November 13, 2006
- PMDA Aims at Global Simultaneous Review of Groundbreaking Products: Mr Mori
November 13, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…